|
Living Medical Textbook From Projects In Knowledge |
|
|
Chapter 1 Chemotherapy in Recurrent or Metastatic Cervical Cancer Last Updated: October 03, 2009 |
||
|
Chapter 2 Current Management of Endometrial Cancer Last Updated: October 31, 2009 |
||
|
Chapter 3 Frontline Management of Ovarian Cancer Last Updated: November 26, 2009 |
||
|
Chapter 4 Recurrent Ovarian Cancer: State of the State Last Updated: January 19, 2010 |
||
|
Chapter 5 Early Breast Cancer—Tumor Genetic Profiling in The 21st Century Last Updated: January 23, 2010 |
||
|
Chapter 6 Targeted Agents and Chemotherapy Options for HER2-Positive and HER2-Negative Metastatic Breast Cancer Last Updated: January 30, 2010 |
||
|
| Table of Contents |
|
Chapter 6 - Targeted Agents and Chemotherapy Options for HER2-Positive and HER2-Negative Metastatic Breast Cancer |
|
Treatment goals for advanced, recurrent, and metastatic breast cancer include prolonging survival and improving quality of life. In this chapter, Drs. Patrick Morris and Monica Fornier evaluate current and emerging therapeutic approaches—including neoadjuvant and adjuvant cytotoxics, targeted agents, and novel therapeutics—within the context of the clinical challenges associated with progressive disease.  top |
| |
|
Chapter 5 - Early Breast Cancer—Tumor Genetic Profiling in The 21st Century |
|
Approximately one third of women with early-stage breast cancer will eventually develop metastatic disease, and most are referred for adjuvant chemotherapy following local therapy. In chapter 5, Drs. Patrick Morris and Monica Fornier present strategies to identify patients most likely to benefit from adjuvant chemotherapy. Therapy for early breast cancer can be individualized based on each patient’s risk factors, ascertained through genetic profiles, analysis of circulating tumor cells, and testing for HER2, BRCA1, and BRCA2. top |
| |
|
Chapter 4 - Recurrent Ovarian Cancer: State of the State |
|
In chapter four of the Living Medical Textbook™: Women's Cancers Edition, Robert Coleman, MD, reviews current approaches to the treatment of women with recurrent ovarian cancer. Despite the devastating prognosis of recurrent disease, current and emerging therapies have much to offer in terms of disease control, maintenance of quality of life, and extended survival. Dr. Coleman’s focus on the significance of treatment-free interval and platinum-sensitivity status when choosing second-line therapy will help you select therapeutic regimens most likely to benefit your patients. In addition, his summary of emerging targeted agents and their performance in clinical trials of recurrent disease demonstrates future promising directions for therapy. top |
| |
|
Chapter 3 - Frontline Management of Ovarian Cancer |
|
In chapter three of the Living Medical Textbook™ Women's Cancers Edition, Robert Morris, MD, focuses on detecting, diagnosing, and treating the disease early when enduring response is most likely. His expert opinion and review of the medical literature will help you to interpret early warning signs in your patients and to evaluate the role of frontline therapies, including standard-of-care intravenous and intraperitoneal chemotherapy, neoadjuvant and maintenance therapies, and emerging targeted agents. top |
| |
|
Chapter 2 - Current Management of Endometrial Cancer |
|
Endometrial cancer is the most common gynecologic malignancy. Survival is high in localized disease, but drops dramatically when the disease spreads within or beyond the region. In chapter two of the Living Medical Textbook™: Women's Cancers Edition, Thomas Herzog, MD, discusses prognostic factors and correlates risk of recurrence with adjuvant therapy recommendations based on clinical trial data. Join Dr. Herzog to better formulate current treatment regimens and anticipate developing therapies to improve outcomes for your patients with endometrial cancer. top |
| |
|
Chapter 1 - Chemotherapy in Recurrent or Metastatic Cervical Cancer |
|
Although the incidence of cervical cancer has declined in recent decades, the disease remains common enough to be routinely seen in the practices of oncology clinicians, gynecologists, and primary care physicians. In this first chapter of the Living Medical Textbook™: Women's Cancers Edition, Bradley Monk, MD, provides framework of clinical trials in women with recurrent or metastatic cervical cancer that will help you to understand and formulate treatment options for your patients now, as well as to anticipate the potential role and survival impact of developing chemotherapy regimens and targeted therapies. top |
| |
|
| CME INFORMATION |
ACTIVITY GOAL |
| The goal of these CME activities is to examine current and emerging strategies for treating and managing patients with breast, ovarian, cervical and endometrial cancers. |
TARGET AUDIENCE |
| This series of activities is designed for medical oncology clinicians, gynecologists, primary care physicians and other clinicians who interact with and/or treat women with breast, ovarian, uterine/endometrial, and cervical cancers. |
LEARNING OBJECTIVES |
|
| top1863 |
|
|||
|
|||
|
These independent CME activities are supported by educational grants from
Bristol-Myers Squibb Genentech Inc. Novartis Pharmaceutical Corporation OrthoBiotech Inc. Pfizer Inc.. |
|||
| EDITORIAL BOARD | |||
| CONTRIBUTING EDITOR Robert L. Coleman, MD |
|||
|
|||
| CONTRIBUTING EDITOR Monica Fornier, MD |
|||
|
|||
| CONTRIBUTING EDITOR Thomas J. Herzog, MD |
|||
|
|||
| CONTRIBUTING EDITOR Bradley J. Monk, MD |
|||
|
|||
| CONTRIBUTING EDITOR Robert T. Morris, MD |
|||
|
|||
| CONTRIBUTING EDITOR Patrick G. Morris, MD, MSc, MRCPI |
|||
|
|||
